2026 Q2 -tulosraportti
Vain PDF
30 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 15.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 9.7. | ||
2026 Q1 -tulosraportti 15.4. | ||
2025 Q4 -tulosraportti 21.1. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 31.7.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·17 t sitten · MuokattuPartly, the price of medtech is low, as someone writes. Not least unlisted medtech companies. Partly, Flerie and its main shareholder tried to make the share more attractive and reduce the substance discount, so that the price came closer to the substance value - but the technique was hopelessly opaque for journalists and ordinary market participants and unfortunately ended with the price falling further and the substance discount becoming even higher. Today's low price is due to a difficult-to-understand process, where shareholders received a "payout" of part of the cash holdings and subsequently received additional shares at the main shareholder's expense - without the market and journalists really being able to understand and calculate what the new price should be. It may therefore take a long time before the price of Flerie recovers - but it should. It doesn't get any better that foolish journalists and AI keep driving the share price down when they compare current substance value with last year's substance value without mentioning or recalculating the fall in relation to last year's price in relation to "payout" and free shares since then. I made this updated analysis on 30.06.2026: "The ”real substance discount” is currently 71 % at today's price of 20.20 SEK. This means that you get the unlisted shares for less than 1/3 of the current value. The official substance discount calculated by ibindex.se is 51 % as of today. But note that I do not calculate the discount in the same way as ibindex, as I instead use what I call the real substance discount. I calculate the ”real substance discount” solely in relation to the unlisted shares, by first fully offsetting the value of the listed shares and positive capital including receivables (and offsetting any debt.) After that, it is of course necessary to look at what unlisted shares are in the company's portfolio, and one must consider whether the value is correctly determined. I do not have the prerequisites to know this, and must therefore assess whether I find the management and critics credible and competent, including the extent to which the management itself invests, and whether there are larger investors who sometimes supplement further." DNB Carnegie lowered the target price for Flerie to 26 kronor on July 10, but reiterates buy. At that price, the discount will still be very high.- ·10.7. · MuokattuFlerie reports a net asset value of 39:14 kronor per share as of June 30th. Fine, until one reads the next line in the news. Again, one of these foolish journalists who helps to drag the share price down when it is compared to last year's net asset value without mentioning or recalculating last year's price in relation to "payout" and free shares since then. We probably have to live with the share being kept down in that way in relation to attracting new shareholders and getting the price closer to the large net asset value for the next year or so, until the old comparison figures are gone.
- ·30.6.Updated as of 30.06.2026 The "real substance discount" is currently 71 % at today's price of 20.20 SEK. This means that one acquires the unlisted shares for less than 1/3 of their current value. The low price is due to a difficult-to-understand process where shareholders were "paid out" a portion of the cash holdings and subsequently received additional shares at the main shareholder's expense - without the market and journalists really being able to comprehend and calculate what the new price should be. It may therefore take some time before the price of Flerie recovers - but it should. The official substance discount calculated by ibindex.se is 51 % today. But note that I do not calculate the discount in the same way as ibindex, as I instead use what I call the real substance discount. I calculate the "real substance discount" exclusively in relation to the unlisted shares, by first fully offsetting the value of the listed shares as well as positive capital including receivables (and offsetting any debt.) After that, it is of course necessary to look at what unlisted shares are in the company's portfolio, and one must consider whether the value is correctly determined. I do not have the prerequisites to know this, and must therefore assess whether I find the management and critics credible and competent, including to what extent the management itself invests, and whether there are larger investors who sometimes supplement further.
Very good point that one wants to see other QUALIFIED investors confirm the valuation in the unlisted holdings.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
Vain PDF
30 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·17 t sitten · MuokattuPartly, the price of medtech is low, as someone writes. Not least unlisted medtech companies. Partly, Flerie and its main shareholder tried to make the share more attractive and reduce the substance discount, so that the price came closer to the substance value - but the technique was hopelessly opaque for journalists and ordinary market participants and unfortunately ended with the price falling further and the substance discount becoming even higher. Today's low price is due to a difficult-to-understand process, where shareholders received a "payout" of part of the cash holdings and subsequently received additional shares at the main shareholder's expense - without the market and journalists really being able to understand and calculate what the new price should be. It may therefore take a long time before the price of Flerie recovers - but it should. It doesn't get any better that foolish journalists and AI keep driving the share price down when they compare current substance value with last year's substance value without mentioning or recalculating the fall in relation to last year's price in relation to "payout" and free shares since then. I made this updated analysis on 30.06.2026: "The ”real substance discount” is currently 71 % at today's price of 20.20 SEK. This means that you get the unlisted shares for less than 1/3 of the current value. The official substance discount calculated by ibindex.se is 51 % as of today. But note that I do not calculate the discount in the same way as ibindex, as I instead use what I call the real substance discount. I calculate the ”real substance discount” solely in relation to the unlisted shares, by first fully offsetting the value of the listed shares and positive capital including receivables (and offsetting any debt.) After that, it is of course necessary to look at what unlisted shares are in the company's portfolio, and one must consider whether the value is correctly determined. I do not have the prerequisites to know this, and must therefore assess whether I find the management and critics credible and competent, including the extent to which the management itself invests, and whether there are larger investors who sometimes supplement further." DNB Carnegie lowered the target price for Flerie to 26 kronor on July 10, but reiterates buy. At that price, the discount will still be very high.
- ·10.7. · MuokattuFlerie reports a net asset value of 39:14 kronor per share as of June 30th. Fine, until one reads the next line in the news. Again, one of these foolish journalists who helps to drag the share price down when it is compared to last year's net asset value without mentioning or recalculating last year's price in relation to "payout" and free shares since then. We probably have to live with the share being kept down in that way in relation to attracting new shareholders and getting the price closer to the large net asset value for the next year or so, until the old comparison figures are gone.
- ·30.6.Updated as of 30.06.2026 The "real substance discount" is currently 71 % at today's price of 20.20 SEK. This means that one acquires the unlisted shares for less than 1/3 of their current value. The low price is due to a difficult-to-understand process where shareholders were "paid out" a portion of the cash holdings and subsequently received additional shares at the main shareholder's expense - without the market and journalists really being able to comprehend and calculate what the new price should be. It may therefore take some time before the price of Flerie recovers - but it should. The official substance discount calculated by ibindex.se is 51 % today. But note that I do not calculate the discount in the same way as ibindex, as I instead use what I call the real substance discount. I calculate the "real substance discount" exclusively in relation to the unlisted shares, by first fully offsetting the value of the listed shares as well as positive capital including receivables (and offsetting any debt.) After that, it is of course necessary to look at what unlisted shares are in the company's portfolio, and one must consider whether the value is correctly determined. I do not have the prerequisites to know this, and must therefore assess whether I find the management and critics credible and competent, including to what extent the management itself invests, and whether there are larger investors who sometimes supplement further.Very good point that one wants to see other QUALIFIED investors confirm the valuation in the unlisted holdings.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 15.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 9.7. | ||
2026 Q1 -tulosraportti 15.4. | ||
2025 Q4 -tulosraportti 21.1. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 31.7.2025 |
2026 Q2 -tulosraportti
Vain PDF
30 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 15.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 9.7. | ||
2026 Q1 -tulosraportti 15.4. | ||
2025 Q4 -tulosraportti 21.1. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 31.7.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·17 t sitten · MuokattuPartly, the price of medtech is low, as someone writes. Not least unlisted medtech companies. Partly, Flerie and its main shareholder tried to make the share more attractive and reduce the substance discount, so that the price came closer to the substance value - but the technique was hopelessly opaque for journalists and ordinary market participants and unfortunately ended with the price falling further and the substance discount becoming even higher. Today's low price is due to a difficult-to-understand process, where shareholders received a "payout" of part of the cash holdings and subsequently received additional shares at the main shareholder's expense - without the market and journalists really being able to understand and calculate what the new price should be. It may therefore take a long time before the price of Flerie recovers - but it should. It doesn't get any better that foolish journalists and AI keep driving the share price down when they compare current substance value with last year's substance value without mentioning or recalculating the fall in relation to last year's price in relation to "payout" and free shares since then. I made this updated analysis on 30.06.2026: "The ”real substance discount” is currently 71 % at today's price of 20.20 SEK. This means that you get the unlisted shares for less than 1/3 of the current value. The official substance discount calculated by ibindex.se is 51 % as of today. But note that I do not calculate the discount in the same way as ibindex, as I instead use what I call the real substance discount. I calculate the ”real substance discount” solely in relation to the unlisted shares, by first fully offsetting the value of the listed shares and positive capital including receivables (and offsetting any debt.) After that, it is of course necessary to look at what unlisted shares are in the company's portfolio, and one must consider whether the value is correctly determined. I do not have the prerequisites to know this, and must therefore assess whether I find the management and critics credible and competent, including the extent to which the management itself invests, and whether there are larger investors who sometimes supplement further." DNB Carnegie lowered the target price for Flerie to 26 kronor on July 10, but reiterates buy. At that price, the discount will still be very high.
- ·10.7. · MuokattuFlerie reports a net asset value of 39:14 kronor per share as of June 30th. Fine, until one reads the next line in the news. Again, one of these foolish journalists who helps to drag the share price down when it is compared to last year's net asset value without mentioning or recalculating last year's price in relation to "payout" and free shares since then. We probably have to live with the share being kept down in that way in relation to attracting new shareholders and getting the price closer to the large net asset value for the next year or so, until the old comparison figures are gone.
- ·30.6.Updated as of 30.06.2026 The "real substance discount" is currently 71 % at today's price of 20.20 SEK. This means that one acquires the unlisted shares for less than 1/3 of their current value. The low price is due to a difficult-to-understand process where shareholders were "paid out" a portion of the cash holdings and subsequently received additional shares at the main shareholder's expense - without the market and journalists really being able to comprehend and calculate what the new price should be. It may therefore take some time before the price of Flerie recovers - but it should. The official substance discount calculated by ibindex.se is 51 % today. But note that I do not calculate the discount in the same way as ibindex, as I instead use what I call the real substance discount. I calculate the "real substance discount" exclusively in relation to the unlisted shares, by first fully offsetting the value of the listed shares as well as positive capital including receivables (and offsetting any debt.) After that, it is of course necessary to look at what unlisted shares are in the company's portfolio, and one must consider whether the value is correctly determined. I do not have the prerequisites to know this, and must therefore assess whether I find the management and critics credible and competent, including to what extent the management itself invests, and whether there are larger investors who sometimes supplement further.Very good point that one wants to see other QUALIFIED investors confirm the valuation in the unlisted holdings.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt